Shenzhen Mindray Bio-Medical Electronics Co., Ltd. (SZSE:300760) just released its latest quarterly report and things are not looking great. Shenzhen Mindray Bio-Medical Electronics missed earnings this time around, with CN¥9.0b revenue coming in 9.4% below what the analysts had modelled. Statutory earnings per share (EPS) of CN¥2.54 also fell short of expectations by 13%. Following the result, the analysts have updated their earnings model, and it would be good to know whether they think there's been a strong change in the company's prospects, or if it's business as usual. Readers will be glad to know we've aggregated the latest statutory forecasts to see whether the analysts have changed their mind on Shenzhen Mindray Bio-Medical Electronics after the latest results.

After the latest results, the 31 analysts covering Shenzhen Mindray Bio-Medical Electronics are now predicting revenues of CN¥47.6b in 2025. If met, this would reflect a major 28% improvement in revenue compared to the last 12 months. Statutory earnings per share are predicted to leap 29% to CN¥13.22. Yet prior to the latest earnings, the analysts had been anticipated revenues of CN¥48.3b and earnings per share (EPS) of CN¥13.45 in 2025. So it's pretty clear that, although the analysts have updated their estimates, there's been no major change in expectations for the business following the latest results.

It will come as no surprise then, to learn that the consensus price target is largely unchanged at CN¥357. That's not the only conclusion we can draw from this data however, as some investors also like to consider the spread in estimates when evaluating analyst price targets. Currently, the most bullish analyst values Shenzhen Mindray Bio-Medical Electronics at CN¥418 per share, while the most bearish prices it at CN¥280. These price targets show that analysts do have some differing views on the business, but the estimates do not vary enough to suggest to us that some are betting on wild success or utter failure.

Of course, another way to look at these forecasts is to place them into context against the industry itself. It's clear from the latest estimates that Shenzhen Mindray Bio-Medical Electronics' rate of growth is expected to accelerate meaningfully, with the forecast 22% annualised revenue growth to the end of 2025 noticeably faster than its historical growth of 17% p.a. over the past five years. Other similar companies in the industry (with analyst coverage) are also forecast to grow their revenue at 19% per year. Shenzhen Mindray Bio-Medical Electronics is expected to grow at about the same rate as its industry, so it's not clear that we can draw any conclusions from its growth relative to competitors.

The Bottom Line

The most important thing to take away is that there's been no major change in sentiment, with the analysts reconfirming that the business is performing in line with their previous earnings per share estimates. They also reconfirmed their revenue estimates, with the company predicted to grow at about the same rate as the wider industry. The consensus price target held steady at CN¥357, with the latest estimates not enough to have an impact on their price targets.

Following on from that line of thought, we think that the long-term prospects of the business are much more relevant than next year's earnings. We have forecasts for Shenzhen Mindray Bio-Medical Electronics going out to 2026, and you can see them free on our platform here.

Even so, be aware that Shenzhen Mindray Bio-Medical Electronics is showing 1 warning sign in our investment analysis , you should know about...

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.